Blogs

Be the first person to recommend this.
In this month's Pharmacy SIG literature update: Third auto, K-Mel conditioning and transplant in the setting renal impairment for patients with multiple myeloma. Plus, how does ideal versus total body weight dosing impact busulfan PK? As well as real-world use of defibrotide, reviews of EBV/PTLD and more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion.   ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory ...
0 comments
Be the first person to recommend this.
On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions were generated and reviewed by Syed Abutalib, M.D., Mark R. Litzow, M.D., and William A. Wood, M.D. To take this month’s quiz,  click
0 comments
1 person recommends this.
By Tania Jain, MBBS, Memorial Sloan Kettering Cancer Center Travelling across three time zones to the Clinical Research Training Course in Park City, Utah, on a 6 a.m. flight, I was relatively oblivious of what to expect. Two months ago, when I was accepted for the course, my mentor tweeted that it was a “Great training opportunity for next generation of BMT leaders . ” Reflecting back on the experience, it certainly was that and much more. Not many instances in life have made me feel that fun and learning could be combined, but this was one. Undoubtedly, credit goes to the course co-chairs, the entire faculty team along with the team of coordinators for ...
0 comments
Be the first person to recommend this.
Ongoing education is one of the tenants of this organization. Since its inception in 1993, the incredible people that make up ASBMT have pushed for better regulations, more oversight and a clearer profile of what we do. And for extremely important reasons—our research and our continued push for excellence means our patients are receiving the best care possible. I mention this because in just a few short weeks, we will host our annual Clinical Education Conference (CEC) for NPs, PAs and Fellows in beautiful Nashville, Tenn. Attendees there will have access to the latest in clinical research, fruitful discussions on industry best practices and tips to avoid ...
0 comments
Be the first person to recommend this.
Biomarkers in Chronic Graft-Versus-Host Disease: Quo Vadis? Wolff D, Greinx H, Lee SJ, et al. Bone Marrow Transplantation 2018; 53 (7): 837 According to a study published in Bone Marrow Transplantation , the slower development of biomarkers for diagnosing and treating chronic graft-versus-host disease (cGVHD), compared with acute GVHD, can be attributed to a wider variety of manifestations, overlap with acute GVHD, more variation in time to onset and maximum severity, and a dearth of sufficient patient samples within prospective trials. In March 2017, a North-American and European consortium hosted an international workshop in France to discuss strategies ...
0 comments
Be the first person to recommend this.
Phase I Clinical Trial Evaluating Abatacept in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease Nahas MR, Soiffer RJ, Kim HT, et al. Blood 2018; 131 (25): 2836-2845 Use of abatacept generated a clinical partial response per 2005 National Institutes of Health Consensus Criteria in 44% of patients with steroid-refractory chronic graft-versus-host disease (SR-cGVHD) following allogeneic stem cell transplantation, according to research published in Blood . The Phase I clinical trial with 16 evaluable participants concluded that the drug was well-tolerated with no dose-limiting toxicities. Notably, use of abatacept led to a 51.3% reduction ...
0 comments
Be the first person to recommend this.
FACT Accreditation a Criterion for 2018-2019 Best Children’s Hospitals List The U.S. News & World Report released the 2018-19 Best Children's Hospitals rankings. The rankings help families of children with complex and rare conditions find medical care. The methodology used FACT accreditation as a criterion that represents high-quality, hospital-based care in the cancer specialty. A hospital was awarded one point if it was accredited by FACT as a pediatric or adult service provider for either autologous or allogeneic transplants. All hospitals on the Best Children’s Hospitals list for cancer are accredited by FACT. Congratulations to these hospitals! ...
0 comments
Be the first person to recommend this.
By Stephanie Farnia, ASBMT Director of Health Policy and Strategic Relations As you know from previous columns, there seems to be an ever-expanding set of health policy issues for ASBMT members to understand. Given that demand, I’m very happy to have Joe Nahra, a member of the ASBMT team in Washington, D.C., helping to monitor and summarize key issues. Joe graduated from the University of Pennsylvania with a focus in public policy; he tracks issues of interest specific to healthcare for associations.     2019 Medicare Inpatient Prospective Payment System Final Rule Released On August 6, CMS released its final rule updating the Medicare Inpatient Prospective ...
0 comments
Be the first person to recommend this.
This article appeared in the July 2018 issue of ASBMT eNews. Download the full issue  in PDF format here . On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions were generated and reviewed by Syed Abutalib, M.D., Mark R. Litzow, ...
0 comments
Be the first person to recommend this.
In this month's Pharmacy SIG literature update: Is tocilizumab effective for SR-GVHD? Can you prevent HHV6 infections in cord blood transplants by using prophylactic foscarnet?  Is defibrotide effective in non-transplant VOD/SOS? Extended follow up data of patient receiving nivolumab post auto-HCT. As well as additional data affirming safety of HCT in the HIV-positive population, and more! _ Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion.   ***        Must read. Landmark publication that affects practice **           Recommend ...
0 comments
Be the first person to recommend this.
July 2018 Download the full issue in PDF format here .  July 2018: A Message from the President The nature of associations is to change. Change is a necessity in an advancing field like ours, but for an association, it’s needed to stay ahead of the curve, exceed expectations and carve new paths for their audience. The field of blood and marrow transplantation itself wouldn’t be around if it weren’t for change — changing technologies, research and innovation all led to the formation of this field and the initial group of clinicians and researchers that became the foundation for ASBMT.   July 2018: Policy Perspective June was deadline ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the  full issue in PDF format here . Researchers Identify Genes Associated With Mortality After Matched Unrelated Donor Transplant Researchers have performed the first exome-wide association study to identify genes that contribute to mortality after HLA-matched unrelated-donor transplantation. The study, published in Blood, included nearly 2,500 patients with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome and more than 2,200 patients with 10/10 HLA-matched donors. Researchers discovered that variant genotypes of OR51D1 in transplant recipients were associated ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the  full issue in PDF format here .  Study Compares Standards and Accreditation A comparison of cord blood banking standards and voluntary accreditations has been completed by the Cord Blood Association (CBA) Quality Standards Committee. The committee’s report is the result of an extensive review and analysis of banking standards, as well as questions posed to AABB and the Foundation for the Accreditation of Cellular Therapy (FACT). The report compares: ways in which the standards are identical, similar and different each agency’s standards development process methods by which ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the  full issue in PDF format here .  All session recordings from the 2018 BMT Tandem Meetings are available! Registered attendees can purchase and download available recordings for a flat fee. Were you not able to join us in Salt Lake City? Not to worry; non-attendees can purchase individual sessions as well. Follow the below instructions for accessing the recordings based on your registration for the 2018 Tandem Meetings. If you have any questions or issues, please reach out to the Conference Office at TCTMeetings@mcw.edu . For Registered Attendees To purchase and download available ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the  full issue in PDF format here .  By Stephanie Farnia, ASBMT Director of Health Policy and Strategic Relations June was deadline month – the CMS NCA for CAR-T, the IPPS rule and several presentation due dates on top of it all. On June 14, we held our second Town Hall session — these are more informal opportunities for me to connect with members on key health policy issues that come up. I would welcome your feedback, as we plan to hold more of these Town Hall events as other important matters come about for ASBMT members. If you were unable to join the town hall, you can download the ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the  full issue in PDF format here . ASBMT Selects Andre Williams as New Executive Director ASBMT is pleased to announce that we have completed the selection process for ASBMT's new executive director. Following a thoughtful review process, ASBMT leadership has unanimously selected Andre Williams to serve as executive director effective July 1.  Andre brings substantial knowledge, skills, and experience to ASBMT from his career serving as executive director of both clinician and translational science organizations. He also has a deep understanding of healthcare reimbursement, having served ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the  full issue in PDF format here . Better Overall Survival After Autologous Transplant for Early Therapy Failure Follicular lymphoma patients who receive autologous hematopoietic cell transplantation for early therapy failure have better overall survival than patients who do not receive an autologous transplant, reports a study published in Biology of Blood and Marrow Transplantation . Researchers analyzed data from 175 patients who received autologous transplantation and 174 patients who did not. All of the patients experienced early therapy failure after frontline chemotherapy. Patients ...
0 comments
Be the first person to recommend this.
This article is part of the July 2018 issue of ASBMT eNews. View the   full issue in PDF format here . A Word from ASBMT President, John F. DiPersio, M.D., Ph.D. The nature of associations is to change. Change is a necessity in an advancing field like ours, but for an association, it’s needed to stay ahead of the curve, exceed expectations and carve new paths for their audience. The field of blood and marrow transplantation itself wouldn’t be around if it weren’t for change — changing technologies, research and innovation all led to the formation of this field and the initial group of clinicians and researchers that became the foundation for ASBMT.   ...
0 comments
Be the first person to recommend this.
June 2018 Download the full issue in PDF format here .  June 2018: A Message from the President As researchers and clinicians, our work is rooted in the public good. We get out of bed every single day not only to help patients but to literally save their lives. Our work is incredibly important for our patients because it can lead to them continuing to live an abundant, long life. June 2018: Policy Perspective We all have mental associations with summer — school being out, trips “up north” (as we like to say here in Wisconsin), ice cream, the sound of the lawn mower and so much more. My summer days center around early morning rows ...
0 comments
Be the first person to recommend this.
This article appeared in the June 2018 issue of ASBMT eNews. Download the full issue  in PDF format here . By Mikaela VanMoorleghem, Education and Training Coordinator, Foundation for the Accreditation of Cellualar Therapy FACT Awards First Accreditation Under the New FACT Standards for Immune Effector Cells FACT awarded accreditation for immune effector cellular therapy under the new FACT Standards for Immune Effector Cells to The University of Texas MD Anderson CARTOX Program, directed by Elizabeth Shpall, M.D., and Sattva S. Neelapu, M.D. This is the first accreditation FACT has awarded to an immune effector cellular therapy program that is independent ...
0 comments